Bio-Techne Corp (TECH) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.

Total Cash From Operating Activities Chart for Bio-Techne Corp

Bio-Techne Corp (TECH) operating cash flow for FY2026 was USD 292.1M, a 1.6% change from FY2025. Bio-Techne Corp's operating cash flow grew from USD 1.1M in 1990 to USD 292.1M in 2026 (26452.1% over 36 years). Operating cash flow compound annual growth rate: 5-year CAGR of -3.7%, 10-year CAGR of 7.3%, 20-year CAGR of 6.3%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$11.28B
Implied Share Price
$72.40
Enterprise Value
$11.31B
Revenue (TTM)
$1.22B
EBITDA
$355.05M
Profit Margin
14.97%
Trailing P/E
62.41
Forward P/E
34.60
Price/Book (MRQ)
5.35
Price/Sales (TTM)
9.28
EV/EBITDA
32.37
EV/Revenue
9.31
Dividend Yield
0.44%
Book Value
$13.32
Free Cash Flow (FY2026)
$263.22M
Free Cash Flow Yield
2.33%

Snapshot as of 16th August 2026 — not point-in-time controlled, may lag the live market by a few days.